EDAP TMS S.A. Launches www.HIFU-Planet.com

Online Tools Help Patients, Doctors Learn About HIFU Options, Benefits in Treating Localized Prostate Cancer



LYON, France, April 21  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP) announced the launch of http://www.hifu-planet.com/ , an online education resource to help both patients and doctors learn about high intensity focused ultrasound treatment of localized prostate cancer.  EDAP is considered the global leader in HIFU treatment of localized prostate cancer through its industry-leading Ablatherm-HIFU unit, which has been in use in Europe for now more than 10 years with excellent clinical outcomes and low side effects. Ablatherm-HIFU has the largest body of clinical experience and data of any HIFU therapy for localized prostate cancer.

"EDAP is aggressively expanding its education efforts directed to patients and doctors now that the Ablatherm-HIFU has clear and credible long-term outcomes supporting it as a clear option for localized prostate cancer," said Fabrice Romano, Director of Marketing for EDAP. "In 2005 the company focused on growing its user base to reach a broader population achieving a 50% increase in sites in just one year and a sustainable growth pattern. With now more than 105 sites we are broadening our efforts to include not only launching new centers but also reaching out to potential patients to drive more treatments at centers using Ablatherm-HIFU. The company's recent success at the EAU Congress in Paris clearly demonstrated the significant upwelling of doctor interest based on the clinical success of Ablatherm-HIFU. With this strong support from the medical community we are now able to reach out directly to patients and help them learn about an effective and attractive treatment option, which may offer them advantages compared to their present choices. This new program and others will help to increase the number of patients treated at current and future centers making Ablatherm-HIFU therapy even more prevalent in the urology and patient communities."

The site offers patients and doctors basic information about HIFU treatment, its effectiveness as reported in multiple clinical studies, patient testimonials, interactive discussions and the considerations in determining if HIFU therapy should be in the list of choices considered by patients as they consult with their physician. A 3-D video description of the Ablatherm-HIFU treatment process is also available on the site to help patients and doctors understand how the treatment works. Patients wanting to learn more can also submit questions through an interactive anonymous Q&A answered by medical professionals experienced in the use of Ablatherm-HIFU. The questions and answers will be archived online helping add to the depth of knowledge on HIFU on the site. Patients interested in pursuing Ablatherm-HIFU can locate a center near their home if they wish to schedule a consultation with medical staff experienced in the use of Ablatherm-HIFU to treat localized prostate cancer.

"EDAP and the Ablatherm-HIFU have been carefully tested by top medical professionals throughout Europe with excellent clinical outcomes in efficacy against localized prostate cancer while keeping side effects very low," said Rafael Varona, Medical Director of EDAP. "We see more patients and doctors now electing to pursue Ablatherm-HIFU because it is the only HIFU therapy that can provide detailed, long-term results from multiple centers demonstrating its success for both first indication and salvage therapy patients. Ablatherm-HIFU helps patients maintain a better quality of life providing rapid treatment averaging less than two hours, quick recovery measured in days or weeks rather than months, and less need for follow up care on side effects that can reduce a patient's ability to pursue the activities they enjoy. But perhaps our best advocates are the patients who have been treated over the past 10 years who can excitedly attest to the benefits of this therapeutic choice."

Recent long-term clinical data demonstrate Ablatherm-HIFU is successful as a curative option for localized prostate cancer in up to 93 percent of patients following treatment. Patients are able to confirm their success by PSA or biopsy accurately within just 3 months of treatment. Incontinence occurred in less than 2 percent of patients. As a salvage therapy, Ablatherm- HIFU demonstrated a success rate of 76 percent on patients who failed prior radiation therapy, many of whom were considered untreatable by traditional methods. Doctors experienced in Ablatherm-HIFU will be able to discuss the clinical studies as they apply to each patient's unique case as well as advantages of Ablatherm-HIFU as compared to other options as they work with the patient to make an informed decision about the best course of care.

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option or patients who failed radiotherapy treatment. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at [phone], the Corporate Investor Relations Dept at [phone] or see the Company's Web sites at http://www.edap-tms.com/ and http://www.hifu-planet.com/ .

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

   CONTACT: EDAP TMS S.A.
            Hugues de Bantel - Philippe Chauveau
            Blandine Confort
            [phone]

            Halliburton Investor Relations
            Matt Kreps - Geralyn DeBusk
            972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all

of EDAP TMS S.A., [phone]; or Matt Kreps, or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/

http://www.hifu-planet.com/ 

Copyright